

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **PROFIT WARNING – FURTHER ANNOUNCEMENT**

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company’s profit warning announcement dated 17 February 2023 in respect of the Company’s financial performance for FY 2022 (“**Announcement**”). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Company was expected to record a loss of not less than HK\$65.6 million for FY2022.

The Board wishes to further inform shareholders of the Company and potential investors that, subsequent to the publication of the Announcement, with further updated information having been made available to the Board, the Board estimated that the Group’s expected loss for FY 2022 may be increased to approximately HK\$77.9 million. The increase in the Group’s expected loss by approximately HK\$12.3 million (as compared with the original estimation of HK\$65.6 million) is primarily due to (i) the recognition of the additional impairment losses on inventories of approximately HK\$9.8 million for FY 2022 in respect of the slow-moving inventories which were close to their expiry date; and (ii) the recognition of the impairment loss on trade and other receivables of approximately HK\$4.6 million.

The Company is still in the process of preparing and finalising its unaudited consolidated financial statements for FY 2022. The information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change or adjustments. Shareholders and potential investors are advised to refer to the details of the Group's financial results for FY 2022, which are expected to be published in 29 March 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman & Executive Director*

Hong Kong, 22 March 2023

*As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*